Navigation Links
Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
Date:11/4/2013

LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of RG-101 will be presented in a late-breaking poster session at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being held in Washington, D.C. on Monday, November 4, 2013 from 8:00 a.m. Eastern Standard Time (EST) to 5:30 p.m. EST. The poster is available on the Company's website at http://www.regulusrx.com.        

"RG-101 utilizes a unique mechanism of action by targeting microRNA-122, a liver-specific host factor for stability, replication and translation of HCV.  We believe that therapies that target host-encoded factors essential for HCV replication may act as attractive combination agents because they may demonstrate activity across all HCV genotypes and may have a high barrier to resistance," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  "We continue to be encouraged by the preclinical data seen to date and believe that RG-101 has the potential to be a best-in-class host factor agent.  In the near term, we expect to file our application with regulatory authorities and look forward to commencing clinical trials in man in early 2014."

Late-Breaking Poster on RG-101 – Monday, November 4, 2013, 8:00 a.m. EST – 5:30 p.m. EST

-RG-101, a GalNAc-conjugated anti-miR Employing a Unique Mechanism of Action by Targeting Host Factor MicroRNA-122 (miR-122), Demonstrates Potent Activity and Reduction of HCV in Preclinical Studies- '/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
3. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. LX4211 Achieves Positive Results in Type 2 Diabetes Patients with Renal Impairment
7. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
8. Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
9. John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
10. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
11. Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... 16, 2014 Eight finalists, all representing outstanding ... present their proposals for a chance to compete for ... Sheikh Zayed Institute Second Annual Pediatric Surgical Innovation Symposium ... on Friday, Oct. 24, 2014. Selected from ... the US and internationally, the finalists are: ...
(Date:10/16/2014)... 16, 2014 Curtis & Coulter LLC, a ... away from hosting their co-located Bioequivalence: Intersection Between ... Formulation Innovations Summit taking place on November 5-6 ... November,s events are specifically designed ... the bioequivalence testing process, as well as optimizing formulation ...
(Date:10/16/2014)... 2014  Personna Industrial, the world,s leading manufacturer of ... and safety systems will be exhibiting at the MD&M ... on October 29-30th. Personna Industrial,s booth is #847. MD&M ... for medical device design and manufacturing professionals. The MD&M ... and applications that are redefining the medical device manufacturing ...
Breaking Medicine Technology:Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2Personna Industrial Exhibiting Among Top Suppliers To Medical Industry At MD&M Minneapolis 2
... public health, and regulatory highlights for this week from ... document is designed for credentialed journalists. Release dates and ... 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... any regulatory or enforcement actions due to legal limitations. ...
... YORK,  June 6, 2011 Aeolus Pharmaceuticals, Inc. (OTCQB: ... is available for on-demand viewing. LINK: ... button. Aeolus Pharmaceuticals, presentation will be available ... the "virtual trade booth" for the next three weeks. ...
Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Aeolus Pharmaceuticals, Inc. Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com 2
(Date:10/19/2014)... (PRWEB) October 19, 2014 According to ... (NINDS) the vast majority of adults (up to ... point in their lives, spending at least $50 billion ... pain includes; spinal instability, stenosis, spondylolisthesis, and symptomatic degenerative ... by wear and tear associated with the aging process, ...
(Date:10/18/2014)... Riverdale, NY (PRWEB) October 19, 2014 ... Center, specializing in long-term and rehabilitation care in the ... Carlos G. Beato, chief executive officer, was honored by ... with the CHA Corporate Alumni award at their 30th ... science degree in healthcare administration from New Jersey City ...
(Date:10/18/2014)... October 19, 2014 The ... that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), JustHost and ... in 2014. , “There are thousands ... but good suppliers are not too many. ... FatCow are the most outstanding suppliers when ...
(Date:10/18/2014)... October 19, 2014 Web hosting provides ... in websites in recent years, and the new demand ... web hosting companies that offer a variety of different ... USA has compared a lot of professional Windows web ... Bluehost ( http://www.bluehost.com/track/seohosts ), InMotion and Arvixe are the ...
(Date:10/18/2014)... College of Neuropsychopharmacology (ECNP) is pleased to announce that ... Dick Swaab, for his book, We are our Brains: ... ECNP Media Award recognises outstanding contributions to destigmatising disorders ... of € 5,000. , The ECNP Media Award was ... a better understanding of the complexity and impact of ...
Breaking Medicine News(10 mins):Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 2Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 5Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 2Health News:Carlos G. Beato Honored by New Jersey City University’s Council on Hispanic Affairs (CHA) 3Health News:Top10BestSEOHosting.com: Best Reseller Hosting Companies Announced 2Health News:Best Web Hosting Companies In 2014 Released By SEO Hosting Review Site Best Cheap Hosting USA 2Health News:Dick Swaab wins the 2014 ECNP Media Award 2
... Israel, Nov. 29 Elbit Imaging Ltd.,(TASE, Nasdaq: ... November,28, 2007, InSightec Ltd. ("InSightec"), a subsidiary of ... an agreement for an internal,round of financing in ... existing,investors, namely: Elbit Ultrasound (Netherlands) B.V., a fully ...
... Satellite Newsfeed Notification ... Friday, 11/30, WASHINGTON, Nov. 29 , ... more than 19,million Americans. Despite its prevalence, depression ... is a,first-of-its-kind study examining the statistical relationship between ...
... benefit for the female hormone , THURSDAY, Nov. 29 ... which is often given with estrogen in hormone replacement ... U.S. researchers say. , They conducted tests on female ... come to this conclusion. , Treatment with estrogen blocked ...
... Week to Experience the, World,s Most Advanced Laparoscopic Surgery ... ... Congress, CLEVELAND, Ohio, November 29 Simbionix unveiled the,latest module ... Global Congress of Minimally Invasive Gynecology., The LAP Mentor(TM) multidisciplinary ...
... Utah, Nov. 29 Nutraceutical,International Corporation (Nasdaq: NUTR ... and year ended September 30, 2007., Net sales ... to $35.7 million for the same quarter of fiscal ... or $0.23 diluted earnings per,share, compared to net income ...
... 29 InSightec Ltd. today,reported that it has closed ... existing investors: Elbit Imaging Ltd. (Nasdaq: EMITF ), ... Company,(NYSE: GE ), MediTech Advisors LLC ("MTA"), a ... managers of the company., The investment will take ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 2Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 3Health News:Elbit Imaging Ltd. Announces US$19,829,643 Investment in its Subsidiary InSightec Ltd., in an Internal Round of Financing 4Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 2Health News:Ranking America's Mental Health: An Analysis of Depression Across the States 3Health News:Progesterone Won't Shield Women Against Alzheimer's 2Health News:Gynecologists Get First Hands-On Experience With Simbionix LAP Mentor(TM) 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 2Health News:Nutraceutical Reports 2007 Fiscal Year End Results 3Health News:Nutraceutical Reports 2007 Fiscal Year End Results 4Health News:Nutraceutical Reports 2007 Fiscal Year End Results 5Health News:Nutraceutical Reports 2007 Fiscal Year End Results 6Health News:InSightec Ltd. Announces US$30 Million Investment Round 2Health News:InSightec Ltd. Announces US$30 Million Investment Round 3
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... (iopamidol injection) is a safe and effective ... clinical experience since 1986. Worldwide, more ... been administered. Indicated for a wide ... flexibility by providing a wide range of ...
... MR contrast agent FDA-approved for administration by ... based, IV contrast media for MR imaging ... has convenient packaging options for just ... efficient, problem-free delivery. You can trust OptiMARK® ...
... contrast agent approved for sale in the ... the Amersham Health portfolio to include an ... aids in the detection, localization, characterization, and ... within minutes of injection, and additional scans ...
Medicine Products: